DARE DARE
Company Profile ↓Company Overview
DARE (DARE) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $1.03M (+10429.4% YoY); net profit $-13.40M.
- 5-Year Trend Long-term compounding — revenue CAGR 6.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -43.93% |
| 6 Months: | -23.86% |
| 3 Months: | -59.02% |
| 1 Month: | -34.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross4d ago
- RSI (14)36.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 59.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | 10.00M | 0 | 0 | 0 | 1.00M | 9.30K | 22.44K | 41.69K | 25.43K | - | 2.26K | 152.46K |
| Operating Income | - | - | - | - | - | - | - | - | - | - | -5.96K | - | -228.46K | -479.62K | -1.33M | -7.68M | -3.62M | -2.62M | -3.08M | -3.98M | -3.42M | -4.25M | -7.13M | -7.58M | -7.69M | -9.16M | -12.67M | -8.40M | 384.32K | -7.14M | -8.38M | -8.99M | -8.40M | -6.02M | -7.36M | -4.68M | -4.58M | -3.83M | -3.67M | -3.00M |
| Net Income | -2.91M | -7.40M | -5.56M | -7.47M | -8.42M | -9.91M | -10.55M | -10.72M | -13.54M | -10.86M | -16.11K | -4.95M | -243.86K | -498.19K | -1.63M | -7.67M | -3.58M | -2.57M | -3.05M | -3.95M | -3.39M | -4.25M | -7.12M | -7.58M | -7.32M | -9.16M | -12.67M | -8.40M | 414.00K | -7.02M | -8.04M | -8.76M | -8.30M | -6.76M | 12.91M | -4.70M | -4.38M | -4.02M | -3.56M | -3.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.27 | -0.24 | -0.16 | -0.18 | -0.18 | -0.10 | 0.00 | -0.08 | -0.09 | -1.22 | -1.09 | -0.81 | 1.52 | -0.55 | -0.50 | -0.45 | -0.28 | -0.21 |
| R&D Expense | 1.50M | 2.65M | 2.93M | 4.70M | 5.02M | 6.68M | 7.09M | 7.16M | 9.77M | 7.52M | 7.09M | 3.18M | 27.80K | 3.58K | 280.79K | 1.09M | 2.22M | 1.45M | 1.69M | 2.51M | 1.97M | 2.38M | 5.55M | 6.20M | 5.73M | 7.34M | 10.43M | 5.81M | 6.80M | 4.46M | 5.02M | 6.04M | 6.67M | 3.35M | 4.93M | 2.68M | 2.30M | 1.43M | 1.18M | 660.46K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 625.00K | 6.00K | 80.00K | - | 766.00K | - | - | - | - | 0 | 10.00M | 2.81M | 9.78K | 1.03M |
| Operating Income | - | - | - | - | -630.59K | -11.18M | -16.88M | -14.34M | -27.40M | -39.07M | -31.39M | -30.94M | -23.45M | -13.55M |
| Net Income | -22.10M | -17.14M | -23.34M | -39.59M | -672.69K | -11.50M | -16.74M | -14.26M | -27.40M | -38.70M | -30.95M | -30.16M | -4.05M | -13.40M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.91 | -0.63 | -0.37 | -4.15 | -0.48 | -1.20 |
| R&D Expense | 15.81M | 9.70M | 11.77M | 25.95M | 72.67K | 984.75K | 6.41M | 8.55M | 20.77M | 30.62M | 30.04M | 21.54M | 14.31M | 5.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 6.83M | 53.39M | 78.22M | 44.61K | 14.26M | 7.83M | 7.44M | 7.55M | 55.81M | 43.83M | 21.28M | 22.10M | 32.47M |
| Total Equity | -58.40M | -80.04M | -94.30M | 45.33M | -46.95K | -710.62K | 13.29M | 6.73M | 440.83K | -1.15M | 38.75M | 11.11M | -5.05M | -6.01M | 2.84M |
| Cash & Equivalents | 15.35M | 16.71M | 5.49M | 51.17M | 219.41K | 44.61K | 7.56M | 6.81M | 4.78M | 4.67M | 51.67M | 34.67M | 10.48M | 15.70M | 24.71M |
| Total Liabilities | - | - | - | - | - | 755.24K | 967.04K | 1.10M | 7.00M | 8.70M | 17.05M | 32.71M | 26.33M | 28.11M | 29.63M |
| Current Liabilities | - | - | 15.15M | 8.06M | 16.34M | 755.24K | 966.65K | 1.09M | 5.61M | 7.66M | 16.05M | 31.62M | 20.48M | 21.61M | 23.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -2.54M | -10.27M | -13.32M | -25.23M | -28.76M | -18.09M | -38.86M | 5.47M | -9.89M |
| Investing Cash Flow | - | - | - | - | - | 9.92M | -518.84K | 6.14M | -17.62K | -14.52K | -63.07K | -629.43K | -573.05K | -385.28K |
| Financing Cash Flow | - | - | - | - | - | 155.00K | 10.11M | 5.15M | 25.13M | 75.85M | 1.34M | 15.64M | 354.52K | 19.28M |
| Capital Expenditure | -180.00K | -7.00K | -225.00K | -277.00K | -535.00K | -0 | -11.84K | -0 | -17.62K | -14.52K | -63.07K | -629.43K | -573.05K | -385.28K |
| Free Cash Flow | - | - | - | - | - | -2.54M | -10.28M | -13.32M | -25.25M | -28.78M | -18.15M | -39.49M | 4.90M | -10.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -82.3% | - | - | - | - | - | -313.9% | -1,101.9% | -239,692.2% | -1,315.5% |
| Net Margin % | -3,536.2% | -285,716.7% | -29,177.5% | - | -87.8% | - | - | - | - | - | -309.5% | -1,074.2% | -41,430.9% | -1,300.7% |
| ROE % | 27.6% | 18.2% | -51.5% | 84,337.7% | 94.7% | -86.5% | -248.8% | -3,235.7% | 2,379.1% | -99.8% | -278.5% | 597.5% | 67.4% | -471.4% |
| ROCE % | - | - | - | - | 88.7% | -84.1% | -250.6% | -783.7% | 24,936.3% | -98.3% | -257.2% | -3,858.9% | -4,805.0% | -154.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DARE
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPSkhmcE1XOTQ4NkJONTg5NXU5eUtoak14Uzc5dGJubTJxUnlVT0xfMTdtWGdsRU0tSER4am43Y0pBR3hraDNmT2p5Z3dyMlRsamFkU0c1aE5XelNmTGhUZk96eHZCM01tRjNOc3QxYm96enR5X2pka29VNzVpWkdIV2FtdHdmR3pVQmhjLU…
Dare Bioscience Received Notice of Delisting - TradingView
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTFpEdXFLSmxEU3pDN1Q4ekVWYnhRRTNZU2RERkYzYjFqX0QyNjgyRnJIQUVocm9GU0daZkNPNGZYZGVQajcydXZHWWVCYnh0cDRSbnA0OU0yMjAzSVNWVDgzWnpjZmowTGc3UWh2TmNMMkV3cGRia3lkUG1pTklncXZqSEI4N1d6ZHVJYl…
DARE|Dare Bioscience Inc|Price:1.285|Chg%:+0.065 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1yNjZPeGNxNzlsRFo4dXp2WGF5N2VfQzZiZEJROEU5S2JPQmxaSXhLaC1tSHlNdGdjNloyMmlzSVBEaWRheUl2U1B0c1EzN3VFY3FmeEIxTmRHdGI1SWhZeFUyS1U1M3pYeEVLNHN3?oc=5" target="_blank">DARE|Dare Bioscienc…
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNV1dZTVJpcGRpUS1tTVhtZi1Tc3VRbEpWN3VtZ2lUaVc0NmVzamZ0RmEybTRkbzhfRWltb3FMcktEM3ZLQ0dyRnFjWm9LNVV5QzY3eTQ1RUlISHIyUnlnMFVSajlIS0I2d3ZZbmdOR0loN1RLSUNoUW5wRnItNFJVbUt2cWMwVTBOZGU1Vn…
Women Exploring DARE to PLAY Can Now Reach Menopause Specialists - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNVGhaOXpkZEZsZFVMSncySWFKdkJad1BJcVk5X1kwYS1WaFN0R1NpOVhjb1llLURlWkU5TnBDaHNYbDZBcU8yTlhXbXhVazl1YWhVYjdSN2Zlbms2eGtTTWRFSzZvcXcyN2FRLVNWdWhrdnhSLXZ6UmlEQW1BUHBGbUZUUjFBU0tjeUdvRk…
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxNS2dyNEhRWmtTckpTakhXNGVxOFc5OXZoQ2JWN09jZFJweHZFR1c0X2lBU3dGRGNaQWlyQl9uTTVoVXBUbVBRcmR2NE5ib21vOFpOXzBaemhLTWFOWDdEUEZSOUdEdUJZNGEzY1RSNFJidzVQc0lYSndhS1BIVHExV21Tb0xVLW5EbWlhaF…
DARE — Frequently Asked Questions
What is the current share price of DARE?
As of 2026-08-05 17:25 PDT, DARE trades at $1.34 on NASDAQ/NYSE. Its 52-week range is $1.16 to $3.27.
What is the P/E ratio of DARE?
DARE trades at a trailing price-to-earnings (P/E) ratio of -1.12.
Is DARE a good stock to buy?
This page provides a data-driven analysis of DARE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.